Many new drugs did not have comparative effectiveness information available at time of FDA approval, study finds

Only about half of new drugs approved in the last decade had comparative effectiveness data available at the time of their approval by the US Food and Drug Administration, and approximately two-thirds of new drugs had this information available when alternative treatment options existed, according to a new study.